Direct Biologics is a market leading innovator and cGMP manufacturer of regenerative biologic products, including ExoFlo.
Direct Biologics has raised $35.1M in total funding. The most recent round was Series B. The last funding was announced in October 2022.
Direct Biologics is headquartered in Austin, United States.
Direct Biologics is a market leading innovator and cGMP manufacturer of regenerative biologic products, including ExoFlo.
Direct Biologics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Direct Biologics — Funding & Investors." VCBacked, October 1, 2022, https://www.vcbacked.co/company/direct-biologics. Accessed August 13, 2026.
VCBacked. (2022). Direct Biologics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/direct-biologics
{{cite web |title=Direct Biologics — Funding & Investors |url=https://www.vcbacked.co/company/direct-biologics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated